ADAPTIVE BIOTECHNOLOGIES CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $12.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $12.30M, a 6050.00% increase from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $200.00K, a 85.71% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.40M, a 81.58% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $7.60M, a 95.14% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $12.30M 10-K · filed 2026-02-26 |
| 2024-12-31 | $200.00K 10-K · filed 2026-02-26 |
| 2023-12-31 | $1.40M 10-K · filed 2026-02-26 |
| 2022-12-31 | $7.60M 10-K · filed 2025-03-03 |
| 2021-12-31 | $156.50M 10-K · filed 2024-02-29 |
| 2020-12-31 | $190.40M 10-K · filed 2023-02-14 |
| 2019-12-31 | $39.10M 10-K · filed 2022-02-15 |
| 2018-12-31 | $3.80M 10-K · filed 2021-02-24 |
| 2017-12-31 | $1.30M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |